SINOVAC BIOTECH BEGINS PANDEMIC FLU VACCINE CLINICAL TRIALS

A A

Sinovac Biotech has initiated clinical trials for its pandemic flu (H5N1) vaccine Panflu. The vaccine was administered to the first six volunteers at the Beijing Sino-Japan Friendship Hospital in Beijing, China.

Due to this vaccine's mature technology, China's State Food and Drug Administration has approved modification to fast-track the clinical trial process from three stages to only two stages. Stage I includes 120 healthy volunteers, aged 18 to 60, and is expected to take nine-months. Preliminary results should be available by the end of March 2006.